Oncocyte Corporation - Common Shares, No Par Value (OCX)

Historical Holders from Q4 2015 to Q2 2025

Symbol
OCX on Nasdaq
Type / Class
Equity / Common Shares, No Par Value
Shares outstanding
28,495,649
All holders as of 30 Jun 2025
Q2 2025
Total 13F shares, excl. options
0
Holdings value
$0
Number of holders
0
Number of sells
-1
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Oncocyte Corporation - Common Shares, No Par Value (OCX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIO-RAD LABORATORIES, INC. 9.7% $608,097 2,764,078 BIO-RAD LABORATORIES, INC 10 Feb 2025
SMITH PATRICK W 10.5% $4,221,889 1,773,903 Patrick W. Smith 26 Dec 2024

Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q2 0 $0 -$126,921 0
2025 Q1 44,378 $126,921 -$7,722 $2.86 1
2024 Q4 47,078 $112,046 -$29,215 $2.38 1
2024 Q3 59,353 $169,156 -$3,224,887 $2.85 1
2024 Q2 1,152,395 $3,399,565 +$1,009,560 $2.95 2
2024 Q1 810,171 $2,373,801 -$46,191 $2.93 2
2023 Q4 825,936 $2,049,754 -$20,365 $2.49 2
2023 Q3 833,802 $2,716,547 -$68,395,020 $3.2 2
2023 Q2 91,821,550 $21,118,229 +$8,239,978 $0.23 45
2023 Q1 55,657,631 $19,725,177 -$1,788,149 $0.3544 51
2022 Q4 60,727,357 $19,486,077 -$2,603,944 $0.3209 55
2022 Q3 66,115,361 $48,286,884 -$1,938,715 $0.7308 55
2022 Q2 68,689,787 $61,801,567 +$12,093,920 $0.8999 64
2022 Q1 54,297,692 $81,004,102 -$2,234,275 $1.49 76
2021 Q4 55,309,802 $119,904,059 -$4,932,956 $2.17 82
2021 Q3 56,556,369 $201,842,971 -$4,273,319 $3.56 91
2021 Q2 56,557,145 $324,629,337 +$10,097,713 $5.74 88
2021 Q1 54,525,746 $282,982,492 +$112,979,747 $5.19 84
2020 Q4 32,820,981 $78,442,746 +$4,663,024 $2.39 56
2020 Q3 31,284,691 $43,477,422 -$4,537,534 $1.39 55
2020 Q2 32,913,612 $62,907,536 +$9,179,739 $1.91 57
2020 Q1 27,664,198 $67,748,452 +$4,418,527 $2.45 52
2019 Q4 25,884,634 $58,219,716 +$15,568,577 $2.25 50
2019 Q3 18,982,051 $39,859,066 +$6,042,313 $2.1 53
2019 Q2 15,958,159 $39,753,182 -$2,942,657 $2.49 48
2019 Q1 16,115,175 $63,651,620 +$30,829,652 $3.95 45
2018 Q4 8,316,794 $11,476,217 -$815,784 $1.38 14
2018 Q3 8,717,557 $21,792,392 -$155,396 $2.5 20
2018 Q2 8,778,305 $22,385,400 +$392,217 $2.55 24
2018 Q1 8,633,348 $18,127,749 +$8,211,749 $2.1 27
2017 Q4 4,675,016 $21,738,469 +$1,170,257 $4.65 32
2017 Q3 4,410,134 $33,296,650 +$3,970,096 $7.55 28
2017 Q2 3,900,811 $20,278,960 +$545,423 $5.19 30
2017 Q1 3,775,245 $22,466,000 +$4,356,561 $5.94 25
2016 Q4 3,124,915 $22,028,000 +$338,627 $7.05 24
2016 Q3 3,076,924 $15,505,000 +$7,596,691 $5.02 20
2016 Q2 1,582,033 $5,632,178 -$394,497 $3.56 24
2016 Q1 1,668,822 $7,688,812 +$2,644,415 $4.61 35
2015 Q4 1,094,163 $6,839,000 +$6,839,000 $6.24 4